TIDMAPH

RNS Number : 5077A

Alliance Pharma PLC

22 January 2020

 
                                              22 January 2020

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

Full Year Trading Update

Strong revenue growth in 2019 with rapid reduction in net debt

Alliance Pharma plc (AIM: APH), the international healthcare group, announces its unaudited trading update for the year ended 31 December 2019 ahead of the announcement of the Group's audited results on 24 March 2020.

See-through revenue* for 2019 showed strong growth of 16% on the prior year at GBP144.3m (2018: GBP124.0m) on both a reported and constant currency basis. Excluding acquisitions, year on year revenue increased 9% in 2019 (up 8% on a constant currency basis). Underlying profit before tax is expected to be in line with expectations.

Revenue growth was underpinned by strong performances across our International Star brands:

-- Kelo-cote(TM) delivered another very strong performance, with revenues of GBP31.0m, an increase of 38% on the prior year (2018: GBP22.5m), due to continued strong demand from the Asia Pacific region

-- Nizoral(TM) (under Johnson & Johnson management in 2019) performed in line with expectations generating see-through revenues* of GBP20.2m, compared with GBP10.9m in the second half of 2018

   --      MacuShield(TM) saw strong growth in 2019, with revenues up 18% at GBP8.2m (2018: GBP7.0m)

-- Vamousse(TM) delivered another strong performance, achieving revenues of GBP6.5m, up 14% on the previous year (2018: GBP5.8m), and up 10% on a constant currency basis, reflecting continued out-performance against the general market in the US, its main sales territory

Local brands delivered a stable performance with revenues for 2019 slightly ahead of the prior year at GBP78.4m (2018: GBP77.8m).

Free cash flow for the year was very strong at GBP29.1m (2018: GBP16.1m) and continues the first half trend. Net debt reduced to GBP59.2m at 31 December 2019 compared with GBP74.1m at 30 June 2019 and GBP85.8m at 31 December 2018. Leverage (adjusted net debt/EBITDA) was just below 1.5 times as at 31 December 2019 (31 December 2018: 2.3 times).

Peter Butterfield, Chief Executive Officer of Alliance Pharma, commented: "2019 continues the strong momentum of recent years with good organic growth led by our consumer brands. We are also pleased to report very healthy cash generation in 2019, which has resulted in a significant reduction in net debt and leaves us well placed to selectively add to our portfolio with a continued focus on augmenting our consumer brands in international markets. We look forward to 2020 and beyond with confidence."

* See-through revenue includes sales from Nizoral(TM) as if they had been invoiced by Alliance. Under the terms of the transitional services agreement with Johnson & Johnson (J&J), Alliance receives the benefit of the net profit on sales of Nizoral from the date of acquisition up until the product licences in the Asia-Pacific territories transfer from J&J to Alliance. Revenue for 2019, on a statutory-reported basis, is expected to be GBP135.6m, an increase of 15% on the prior year.

For further information:

 
 Alliance Pharma plc                           + 44 (0)1249 466966 
 Peter Butterfield, Chief Executive 
  Officer 
 Andrew Franklin, Chief Financial Officer 
 www.alliancepharma.co.uk 
  Buchanan                                    + 44 (0)20 7466 5000 
 Mark Court / Hannah Ratcliff 
 
 Numis Securities Limited                     + 44 (0)20 7260 1000 
 Nominated Adviser: Freddie Barnfield 
  / Huw Jeremy 
 Corporate Broking: James Black 
 
 
 Investec Bank plc                    + 44 (0)20 7597 5970 
 Corporate Finance: Daniel Adams / 
  Ed Thomas 
 Corporate Broking: Patrick Robb / 
  Tejas Padalkar

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating revenues in more than 100 countries.

We currently own or license the rights to around 90 consumer healthcare products and pharmaceuticals, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused on a small number of brands with significant international or multi-territory reach. The remainder of the portfolio comprises products which are sold in a limited number of local markets and require little or no promotional investment.

Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

TSTSESFAFESSESF

(END) Dow Jones Newswires

January 22, 2020 02:00 ET (07:00 GMT)

Grafico Azioni Alliance Pharma (LSE:APH)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Alliance Pharma
Grafico Azioni Alliance Pharma (LSE:APH)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Alliance Pharma